Halozyme Therapeutics | HALO - Current Assets


Halozyme Therapeutics reported $933.02M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amarin USD 612.88M 10.12M Sep/2026
Amgen USD 34.96B 3.49B Jun/2026
Baxter International USD 6.83B 163M Sep/2026
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Cytokinetics USD 1.21B 369.02M Jun/2026
DBV Technologies USD 189.6M 12.3M Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
MannKind USD 245.71M 5.45M Jun/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Pfizer USD 41.36B 1.46B Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
United Therapeutics USD 3.48B 611.7M Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025